Sign In
Buy IMCR
$33.81
-0.0600 (-0.177%)
At Close: Jul 31, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
07:00am, Thursday, 30'th Jul 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMC
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
12:56pm, Monday, 27'th Jul 2026
IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
12:56pm, Monday, 27'th Jul 2026
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
12:56pm, Monday, 27'th Jul 2026
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
08:34am, Wednesday, 24'th Jun 2026
Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and oper
Is it a Good Idea to Invest in Immunocore Stock Right Now?
11:01am, Wednesday, 17'th Jun 2026
IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.
4 Biotech Stocks Investors Should Watch in 2026
11:55am, Friday, 05'th Jun 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
08:00am, Sunday, 31'st May 2026
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease con
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet
10:56am, Friday, 22'nd May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 111.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the po
Immunocore reports first quarter financial results and provides a business update
07:00am, Wednesday, 06'th May 2026
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
06:00pm, Sunday, 19'th Apr 2026
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
07:00am, Monday, 06'th Apr 2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of “Hold” by Brokerages
04:40am, Tuesday, 31'st Mar 2026
Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the firm, Marketbeat.c
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
04:30pm, Tuesday, 17'th Mar 2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn.
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, "Fool me once, shame on you; fool me twice, shame on me." Well, the buy-the-dip crowd
